Kala Pharmaceuticals Shares Rise Nearly 5% After FDA Fast Track Designation
By Dia Gill
Kala Pharmaceuticals Inc. shares climbed 4.6% to $17.83 during Wednesday morning trading after the U.S. Food and Drug Administration gave Fast Track designation to Kala's human mesenchymal stem cell secretome therapy.
The therapy treats persistent corneal epithelial defect, a rare ocular condition that can cause significant pain and discomfort, vision impairment, and infection. The Fast Track designation is applied to drug candidates that treat serious conditions and have the potential to address an unmet medical need.
In March, the biopharmaceutical company said it received positive safety data from its first cohort of two patients treated with high doses of its treatment.
Shares are down 59% in the past 12 months.
Write to Dia Gill at dia.gill@wsj.com
(END) Dow Jones Newswires
April 12, 2023 10:35 ET (14:35 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth